Early start starting CRIF

Cancer is classified as one of the causes of death all over the world. National Institute of Cancer I mentioned nearly 20 million new cancer cases and 9.7 million cancer -related deaths in the world in 2022, with expectations showing an increase to 29.9 million new cases by 2040.

KrafIt is stopped from Nagoya University in Japan in 2018, Microrna (MIRNA) is used to develop a program to discover early cancer that works for Amnesty International, and has raised $ 22 million of funding from the C series to expand the American market and enhance research and development.

Ryuichi Onose, co -founder and CEO of Craif, told TECHRUNCH in an interview that the company completed the financing round of the chain C with a slightly less than $ 100 million evaluation.

X & kskThe current investor has led the last financing, which raised its total to $ 57 million so far, along with the unreasonable group of the investor based in the United States, its first investment in a Japanese startup, Tunes laboratories, and the Daiwa House Industry and Aozora Bank Group.

Crave’s journey began when Onouz saw the extent of cancer was deeply affected by his family, as his ancestors were diagnosed with the disease. These personal experiences have inspired a strong commitment to helping to address the issue of cancer. Onose and Takao Yasui, Associate Professor at the University of Nagiaa, participated in the establishment of Craif after only one month of their meeting. Yasui has created a new way to detect early on cancer using urinary biomedical indicators.

Onouz said the early detection of a treatment can be a challenge because traditional diagnostic methods such as blood tests can be invasive, which leads to some people avoiding regular examination. In addition, limited access to medical facilities in some areas makes it difficult for individuals to obtain a cancer test easily, according to Onose.

Craif aims to process these gaps by providing a non -surgical test that allows early cancer to be detected, even at a very early stage, as in stage 1.

“The test can be done from the patient’s comfort, and it is operated by an advanced central central analysis, making early detection easier and effective,” said Onoz. “Our users are healthy individuals who are concerned about cancer, but they find that it is difficult to adhere to traditional offers due to time, cost and accessibility.”

Many startups create platforms to detect early cancer in the industry, such as cupand Frinumand Defi Diagnostics and Clearnote Health.

Craif is distinguished by itself using microrna as a vital sign instead of CFDNA (cell -free DNA) like most competitors and urine use.

“Mirna, who gained a great appreciation after linking it to 2024 Nobel PrizeOnose, known for his deep participation in cancer biology even in the early stages.

Another unique aspect of its products is its use of urine. Onose said that urine is easy and non -surgical, as it provides many scientific and practical benefits. He added that it has less impurities than other samples, which makes vital signs more clear. This helps to reduce any errors in the measurement, such as that resulting from the hypothesis of blood in the blood and saves money in the tests.

The first Craif product, a test, which is a test that discovers the risk of seven different cancers (pancreas, colon and rectal, lung, stomach, esophageal breast, ovary) using Mirna urinary, already generates revenues in Japan. Products are distributed through clinics, pharmacies, direct sales of the consumer and well -being programs for companies, providing a variety of revenue sources that can be expanded, according to the CEO of the company.

“We participated in a partnership with more than 1,000 medical institutions and about 600 pharmacists in Japan, where they served about 20,000 users. Our team consists of 73 custom employees.”

The revenue form provides both individual tests and subscription packages for a regular test, as many users choose subscription plans. Revenue has been recorded of $ 5 million in 2024 and aims to generate $ 15 million by the end of this year.

Craig plans to expand the Sernal range to include more than ten different types of cancer next year. Moreover, startups are preparing to use its technology to early detect non -cancerous diseases, such as neurological degenerative disorders such as dementia.

Craif has a R&D laboratory in Irvin, California, and it is intended to open another office in San Diego to deal with his commercial operations.

The new financing will help start entering the United States market through MISINGAL, with the aim of completing experiments in the United States in 2026 and obtaining the approval of the FDA early in 2027.

I have already started collecting pancreatic cancer samples in cooperation with 30 medical institutions in 15 American states.